<DOC>
	<DOCNO>NCT01162122</DOCNO>
	<brief_summary>The present phase III study aim evaluate safety immunogenicity MF59-adjuvanted subunit seasonal influenza vaccine evaluate consistency manufacture process three consecutive lot MF59-adjuvanted subunit seasonal influenza vaccine respect immunogenicity subject age 65 year old . The active comparator non-adjuvanted seasonal influenza vaccine approve use age group United States use provide comparative assessment immunogenicity safety .</brief_summary>
	<brief_title>Safety Immunogenicity MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Males female subject age ≥65 year day vaccination willing able comply study procedure . 1 . Individuals behavioral cognitive impairment psychiatric condition history illness , opinion investigator , would interfere subject 's ability participate study . 2 . Individuals able comprehend and/or follow require study procedure whole period study . 3 . Known suspected impairment/alteration immune function . 4 . Individuals know bleed diathesis . 5 . History GuillainBarré syndrome . 6 . Individuals history allergy vaccine component and/or history anaphylaxis , serious vaccine reaction hypersensitivity influenza viral protein , egg protein ( include ovalbumin ) , polymyxin , neomycin , betapropiolactone , thimerosal/ sodium ethylmercurothiosalicylate/ mercury nonylphenolethoxylate/ nonoxynol9 ( spermicide ) . 7 . Receipt another investigational agent within 30 day prior enrollment study completion safety followup period another study . 8 . Individuals receive vaccine within 2 week inactivate vaccine 4 week live vaccine prior enrollment study plan receive vaccine within 3 week study vaccine . 9 . Individuals receive vaccination seasonal influenza previous 6 month . 10 . Individuals oral temperature ≥38.0°C ( ≥100.4°F ) day study vaccination . 11 . Individuals history substance alcohol abuse within past 2 year . 12 . Individuals provide consent consent retention serum sample study completion . 13 . Elective surgery hospitalization plan occur treatment phase followup phase , accord opinion investigator , might pose additional risk subject . 14 . Subjects blood could draw visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Elderly</keyword>
	<keyword>Influenza</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Adjuvanted</keyword>
	<keyword>Adjuvants</keyword>
	<keyword>Vaccines</keyword>
</DOC>